ZB022
Undisclosed Autoimmune Indication
PreclinicalActive
Key Facts
About Zenas BioPharma
Zenas BioPharma is a clinical-stage biopharma company focused on developing and commercializing therapies for autoimmune diseases. Its strategy centers on acquiring and advancing late-stage assets with validated mechanisms, such as the bifunctional antibody obexelimab and the BTK inhibitor orelabrutinib, to address large market opportunities. The company is led by an experienced team with a proven track record in drug development and commercialization, operating with a patient-centric mission and a sense of urgency.
View full company profileTherapeutic Areas
Other Undisclosed Autoimmune Indication Drugs
| Drug | Company | Phase |
|---|---|---|
| ABCL688 | AbCellera | IND-Enabling |
| ZB021 | Zenas BioPharma | Preclinical |